Korlym (Mifepristone) Patent Expiration, LOE Window & CMS Spending
Korlym (Mifepristone) by Corcept Therapeutics: FDA Orange Book LOE 2038-08-22, 3 AB generics, $409.6M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Corcept Therapeutics |
| FDA Application & Pathway | N202107 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2038-08-22 |
| Orange Book Patents (*PED Extensions) | 18 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 3 |
| 2024 CMS Total Public Spend | $409.6M |
| 2024 Medicare Part D Spend | $341.8M |
| 2024 Medicaid Spend | $67.8M |
| Reported Wholesale Price Change (CA SB 17) | 6 WAC filings (max 25.8% 2-yr change) |